STATROL by Alcon is clinical pharmacology the anti-infective components in statrol ophthalmic ointment provide action against specific organisms susceptible to them. Approved for the topical treatment of infections of the external eye, its adnexa caused by susceptible bacteria. First approved in 1974.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
STATROL is a topical ophthalmic antibiotic ointment combining Polymyxin B Sulfate and Neomycin Sulfate for treating external eye infections. It provides broad-spectrum coverage against common ocular pathogens including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Neisseria species. The combination works through dual mechanisms targeting gram-positive and gram-negative bacteria.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting brand team focus on generic transition planning and potential cost optimization strategies.
CLINICAL PHARMACOLOGY The anti-infective components in STATROL Ophthalmic Ointment provide action against specific organisms susceptible to them. Polymyxin B Sulfate and Neomycin Sulfate are active in vitro against Staphylococcus aureus, Escherichia coli, Klebsiella/Enterobacter species, Neisseria…
Worked on STATROL at Alcon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on STATROL offers limited growth trajectory as the product approaches loss of exclusivity, making it suitable for career roles focused on defensive strategies, generic transition planning, and product lifecycle management. Positions tend to emphasize operational efficiency and stakeholder management rather than market expansion or innovation.